Navigation Links
PharmaNet Extends Consent Payment Deadline for Notes Tendered in Its Tender Offer and Consent Solicitation
Date:6/10/2011

ew York City time, on June 9, 2011. Notes tendered and consents delivered pursuant to the Offer may no longer be withdrawn.

The Offer is subject to a number of conditions that are set forth in the Offer to Purchase and Consent Solicitation Statement dated May 26, 2011 (the "Offer to Purchase"), including, without limitation, (i) the consummation of the Transaction (as defined in the Offer to Purchase), (ii) the receipt of the required consents to amend and supplement the indenture governing the Notes and (iii) the execution and delivery of a supplemental indenture effecting such amendments by the applicable parties, all as more fully described in the Offer to Purchase.

As of 5:00 p.m., New York City time, on June 9, 2011, PharmaNet received tenders of Notes subject to the Offer totaling approximately $73,000,000, or approximately 40%, of the outstanding principal amount of the Notes.

The Company has engaged Jefferies & Company, Inc. and UBS Securities LLC as Dealer Managers and Solicitation Agents for the Offer. Persons with questions regarding the Offer should contact Jefferies at (888) 708-5831 (toll free) or (203) 708-5831 (collect) or UBS Investment Bank at or (888) 719-4210 (toll free) or (203) 719-4210 (collect). Requests for copies of the Offer to Purchase or other tender offer materials may be directed to D.F. King & Co., Inc., the Information Agent, at (800) 967-4607 (toll free).

This press release is for information purposes only and does not constitute an offer to purchase the Notes, a solicitation of an offer to purchase the Notes or a solicitation of a consent to amend the related indenture. The Offer is made solely pursuant to the Offer to Purchase. The Offer is not being made to holders of Notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction.

None of the Company, the Dealer Managers and Solicitation Ag
'/>"/>

SOURCE PharmaNet Development Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PharmaNet Announces Tender Offer and Consent Solicitation
2. PharmaNet to Present More Than 20 Posters at the 2010 American Association of Pharmaceutical Scientists Annual Meeting
3. PharmaNet Development Group Experts to Share Insights at the 9th Annual Partnerships in Clinical Trials Conference in Vienna
4. PharmaNet Development Group Appoints Anthony Maida, Vice President, Clinical Research
5. Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer
6. SEC Closes Investigation of PharmaNet Development Group and Recommends No Action
7. Christopher Brennan Joins PharmaNet Development Group as General Counsel
8. PharmaNet Development Group Provides Financial Update and Announces Geographic Expansion
9. PharmaNet Development Group Clinical Research Experts to Present at Global Professional Meetings in June
10. PharmaNet Development Group Gives Notice of Anticipated Fundamental Change and Merger to Holders of Its Convertible Notes
11. PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... San Diego, California (PRWEB) January 22, 2015 ... R Promotional Offer to their comprehensive portfolio of ... Offer allows customers to purchase a Centrifuge 5424/5424 R ... Pipette Bundle of either Eppendorf Research plus or Eppendorf ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Selexis SA, ... mammalian Research Cell Banks (RCBs) used for drug discovery ... Cell Banks will include Next-Generation Sequencing (NGS) ... architecture de-risks biologic manufacturing by ensuring the integrity of ...
(Date:1/22/2015)... 2015  Varian Medical Systems (NYSE: VAR ), world ... its commitment to sustainability with inclusion on a prestigious list ... ranked healthcare equipment company among the Corporate Knights Global 100 ... Forum at Davos, Switzerland . ...
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval application ... the use of Medtronic,s SynchroMed ® II implantable ... use with United Therapeutics, Remodulin ® (treprostinil) Injection ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... on ... HeartMate II(R), PLEASANTON, Calif., Oct. 30 Thoratec,Corporation (Nasdaq: ... therapies to save, support and restore failing hearts,today said that ... revenues in the same period a year ago., Revenues ...
... (Nasdaq: ANDS ) announced today that it has ... virus (HCV) in Part B of a,two-part protocol designed ... ANA773 is the Company,s investigational oral TLR7 agonist,prodrug. In ... cohort will receive,800 mg of ANA773 every other day ...
... 30 In a joint press conference,Orange Romania ... cellular e-health service., "Health is the fundamental ... why,Orange and Medic4all are launching together the Medic4you ... Services Development,Manager for Orange Romania., Medic4you is ...
Cached Biology Technology:Thoratec Reports 44 Percent Increase in Third Quarter Revenues 2Thoratec Reports 44 Percent Increase in Third Quarter Revenues 3Thoratec Reports 44 Percent Increase in Third Quarter Revenues 4Thoratec Reports 44 Percent Increase in Third Quarter Revenues 5Thoratec Reports 44 Percent Increase in Third Quarter Revenues 6Thoratec Reports 44 Percent Increase in Third Quarter Revenues 7Thoratec Reports 44 Percent Increase in Third Quarter Revenues 8Thoratec Reports 44 Percent Increase in Third Quarter Revenues 9Thoratec Reports 44 Percent Increase in Third Quarter Revenues 10Thoratec Reports 44 Percent Increase in Third Quarter Revenues 11Thoratec Reports 44 Percent Increase in Third Quarter Revenues 12Thoratec Reports 44 Percent Increase in Third Quarter Revenues 13Thoratec Reports 44 Percent Increase in Third Quarter Revenues 14Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients 2Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients 3Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients 4Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients 5Orange and Medic4all Launched the World's First Cellular Tele-Health Service 2
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides ... and fingerprinting markets. Watermarking aims to control and ...
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, today announced ... genetic ancestry of individuals from across the United ... than four hundred years ago, the United States ... from different continents. This study illuminates how American history and ...
(Date:12/17/2014)... 2014  HITLAB SM announced today its completion of ... adherence to current U.S. Food and Drug Administration (FDA) ... device and smart phone application trials utilizing the highest ... "HITLAB is determined to improve global healthcare access, quality, ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... vegetable juice a daily habit could be a small ... daily vegetable recommendations, according to a new study being ... week at the American Dietetic Association annual conference 1 ... short of the daily recommended vegetable intake as put ...
... 23 Paradigm Tactical,Products Inc. (Pink Sheets: PDGT.PK), ... solutions to the military as well as to,the ... agreement,which will make the company the largest distributor ... and four additional detector models in,the United States. ...
... when raised on low calorie diets. But now researchers at ... that they can extend the life spans of roundworms even ... a chemical that blocks their sense of smell. Three ... reported they found that a class of anticonvulsant medications made ...
Cached Biology News:New study shows drinking your vegetables may be a solution to bridging the vegetable gap 2Paradigm Tactical Products to be Largest Distributor of Metal/Radiation Detection Wands in United States 2Paradigm Tactical Products to be Largest Distributor of Metal/Radiation Detection Wands in United States 3Deprived of a sense of smell, worms live longer 2
Immunogen: Synthetic peptide (KLH conjugated): L(506) S K S S S Q I R M S G L P A D N L A T(525) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
BD FastImmune EDTA Solution. Applications: Flow Cytometry Storage Temperature: Refrigerate(2 to 8C)...
... ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C 14 H 15 ... ,M.W.= 408.63 ,Assay: Greater than ... DMF) ,Biological Activity: Blue color with ... Agrees with theoretical values ,Thin Layer ...
Biology Products: